Advertisement
Advertisement
NBTX
Nanobiotix S.A. - ADR
45.49
USDSponsored
+2.88
+6.76%
May 08, 15:59 UTC -4
Closed
After-Market
45.49
0.00
0.00%
NBTX Earnings Reports
Positive Surprise Ratio
NBTX beat 4 of 16 last estimates.
25%
Next Report
Date of Next Report
May 19, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/--
Nanobiotix S.A. - ADR earnings per share and revenue
On Mar 31, 2026, NBTX reported earnings of -0.39 USD per share (EPS) for Q4 25, missing the estimate of 0.55 USD, resulting in a -170.16% surprise. Revenue reached 5.96 million, compared to an expected 59.82 million, with a -90.05% difference. The market reacted with a +10.37% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Nanobiotix S.A. - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Nanobiotix S.A. - ADR reported EPS of -$0.39, missing estimates by -170.16%, and revenue of $5.96M, -90.05% below expectations.
How did the market react to Nanobiotix S.A. - ADR's Q4 2025 earnings?
The stock price moved up 10.37%, changed from $30.87 before the earnings release to $34.07 the day after.
When is Nanobiotix S.A. - ADR expected to report next?
The next earning report is scheduled for May 19, 2026.
What are the forecasts for Nanobiotix S.A. - ADR's next earnings report?
Based on --
analysts, Nanobiotix S.A. - ADR is expected to report EPS of -- and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement